Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.
Ontology highlight
ABSTRACT: CCAAT/enhancer-binding protein-α (C/EBPα/CEBPA) is mutated in approximately 8% of acute myeloid leukemia (AML) in both familial and sporadic AML and, with FLT3 and NPM1, has received most attention as a predictive marker of outcome in patients with normal karyotype disease. Mutations clustering to either the N- or C-terminal (N- and C-ter) portions of the protein have different consequences on the protein function. In familial cases, the N-ter form is inherited with patients exhibiting long latency period before the onset of overt disease, typically with the acquisition of a C-ter mutation. Despite the essential insights murine models provide the functional consequences of wild-type C/EBPα in human hematopoiesis and how different mutations are involved in AML development have received less
SUBMITTER: Quintana-Bustamante O
PROVIDER: S-EPMC3378638 | biostudies-literature | 2012 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA